Open access · CC-BY
via OpenAlex
Senescence in Aging and Alzheimer’s Disease
Aging and Disease · 2025 · ▲ 3 citations
Genomic instability
Telomere attrition
Loss of proteostasis
Mitochondrial dysfunction
Cellular senescence
Altered intercellular communication
Chronic inflammation
Disabled macroautophagy
Senolytics
Human
Preclinical / animal
Review
Abstract
Cellular senescence(definition), once considered a protective mechanism against oncogenesis, is now recognized as a key driver of aging and age-related diseases, including Alzheimer’s disease (AD). In the central nervous system (CNS), senescence-like states emerge in both proliferative and post-mitotic cells—astrocytes, microglia, oligodendrocyte lineage cells, endothelial cells, pericytes, and even neurons—contributing to chronic dysfunction. Canonical pathways, such as p16INK4a-pRB and p53-p21, enforced by persistent DNA damage responses, lead to irreversible cell-cycle arrest. The senescence-associated secretory phenotype (SASP) links intracellular stress to extracellular inflammation, tissue remodeling, and bystander senescence. CNS senescence is triggered by diverse insults, including amyloid-β and tau pathology, oxidative stress, mitochondrial dysfunction(definition), NF-κB and cGAS-STING signaling, impaired proteostasis(definition) and autophagy(definition), telomere(definition) attrition, and genomic instability. Senescence markers in the CNS are heterogeneous, ranging from p16/p21 expression and lamin B1 loss to lipofuscin accumulation and cell type-specific SASP profiles, highlighting the need for multiplexed detection strategies. Targeting senescence has emerged as a promising therapeutic avenue in AD. Senolytics(definition) selectively eliminate senescent cells and improve cognition in preclinical models, while senomorphics aim to suppress harmful phenotypes without inducing cell loss. Early clinical trials suggest feasibility, but challenges remain, including biomarker development, blood-brain barrier penetration, long-term safety, and optimal timing of intervention. This review summarizes recent advances in understanding CNS senescence in aging and AD, explores emerging therapeutic strategies, and outlines future directions emphasizing precision medicine through multi-omic biomarkers, advanced imaging, and stage-specific interventions. Targeting CNS senescence holds potential to delay or alter the course of AD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.14336/ad.2025.1201
- Canonical
- link ↗
- Fetched
- 2026-10-05 MST
Cite this
APA
Sun, L., & Chen, C. (2025). Senescence in Aging and Alzheimer’s Disease. <em>Aging and Disease</em>. https://doi.org/10.14336/ad.2025.1201
Vancouver
Sun L, Chen C. Senescence in Aging and Alzheimer’s Disease. Aging and Disease. 2025. doi:10.14336/ad.2025.1201.
BibTeX
@article{li2025Senesc,
title = {Senescence in Aging and Alzheimer’s Disease},
author = {Li Sun and Chu Chen},
journal = {Aging and Disease},
year = {2025},
doi = {10.14336/ad.2025.1201},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Drug design, development and therapy 2025
Open access · OA
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics.
Genetics and Molecular Research 2026
Open access · CC-BY
CELLULAR SENESCENCE: MOLECULAR MECHANISMS AND SENOLYTIC AND SENOMORPHIC STRATEGIES
Biomolecules 2025
Open access · CC-BY
Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions
Veterinary Pathology 2020
Citation only
Cellular Senescence: Mechanisms, Morphology, and Mouse Models
Seminars in Liver Disease 2025
Citation only
Aging and Aging-Related Senescence in Liver
Seminars in liver disease 2025
Citation only